Single-cell technology accelerates drug discovery and target identification
Life Sciences · Nijmegen · Founded 2022
What they build
QurieGen is a biotechnology company focused on accelerating the drug discovery and development process through its proprietary single-cell technology, QuRIE-seq. This patented technology is designed to decode cellular responses by simultaneously quantifying mRNA molecules, hundreds of membrane proteins, intracellular proteins, and phosphoproteins. The company's approach is based on its ability to "lock" biology, which allows for the creation of timelapse maps of cellular responses. By combining this high-throughput proprietary method for mapping cellular responses with single-cell genomics and data science, QurieGen develops predictive models of disease biology and drug response. This platform is intended to assist in the discovery of new drug targets, the development of more efficient therapies, and the streamlining of the time and costs associated with traditional drug discovery and development. The company is based in Nijmegen, Netherlands, and works with leading pharmaceutical companies.
The people behind it
Who believes in them
QurieGen raised €2.2M in total. The latest known round is Seed (2025).
Where they are
Loading nearby…
Keep exploring